retatrutide triple agonist glp-1 gip glucagon phase 3 2025 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials retatrutide triple agonist glp-1 gip

Newer therapy with potentially greater weight loss in clinical trials

No Legal Responsibility: Any claims, damages, or disputes arising from content published on TechBullion shall be resolved directly with the respective content creator or publisher

These potential side effects, along with alopecia, need to be carefully weighed up against the health benefits for each individual patient

The modified peptide contains 2 Aib substitutions at positions 2 and 20 with a molecular weight of 4.5 kDa

Wu T, Horo witz M, Rayner CK: New insights into the anti-diabetic actions of metformin: from the liver to the gut

In clinical trials, Retatrutide treatment normalized liver fat in 90% of patients with NAFLD over 48 weeks, highlighting its significant impact on liver health